Teva Pharmaceutical Industries Ltd. (TEVA) is slated to announce second quarter 2015 earnings results on Thursday, July 30, before market open. The company released preliminary Q2 results on July 27, estimating $4.97 billion in revenue and non-GAAP earnings of $1.43 per share. The preliminary earnings raised the company's full-year 2015 EPS guidance to be in the range of $5.15 to $5.40, up from the previous range of $5.05 to $5.35. Additionally, Teva announced plans to acquire Allergan Generics for $40.5 billion. Teva expects the deal to benefit its financials by achieving $1.4 billion in cost-saving synergies within two years after the deal closes. This news comes as a surprise as Teva has relentlessly been attempting to acquire Mylan Pharmaceuticals. A handful of Wall Street analysts have weighed in on Teva Pharmaceutical ahead of the company's earnings and in light of its acquisition announcement. Here are the top 4 analysts who cover Teva:

1. Liav Abraham of Citigroup most recently reiterated a Buy rating on Teva on July 27 with a price target of $70 in light of the company's acquisition announcement. Abraham believes the merger will allow Teva to “take advantage of a unique opportunity of consolidation in the global generics industry [and] enhance its financial metrics, including cash flows, in order to enable expansion of its branded portfolio in its core areas of expertise.” All in all, the analyst sees the deal as “highly financially compelling, with double-digit returns to shareholders.”

Liav Abraham has rated Teva 6 times since 2013, earning a 100% success rate recommending the stock and a +25.4% average return per TEVA recommendation when measured over a one-year horizon and no benchmark.

2. Tim Chiang of BTIG last weighed in on Teva on July 7 with a Buy rating and a $77 price target, citing the stock as heavily discounted. Though the analyst forecasts sales of Copaxone, Teva's drug to treat multiple sclerosis,  “to decline by -16% in 2015 and -18% in 2016, [Chiang believes] this is well factored into the Teva valuation which is heavily discounted, trading at 12x our 15 EPS estimate of $5.13.”